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Regenerative capacity of skeletal muscles resides in satellite cells, a self-renewing
population of muscle cells. Several studies are investigating epigenetic mechanisms
that control myogenic proliferation and differentiation to find new approaches that could
boost regeneration of endogenous myogenic progenitor populations. In recent years,
a lot of effort has been applied to purify, expand and manipulate adult stem cells
from muscle tissue. However, this population of endogenous myogenic progenitors in
adults is limited and their access is difficult and invasive. Therefore, other sources of
stem cells with potential to regenerate muscles need to be examined. An excellent
candidate could be a population of adult stromal cells within fat characterized by
mesenchymal properties, which have been termed adipose-derived stem cells (ASCs).
These progenitor adult stem cells have been successfully differentiated in vitro to
osteogenic, chondrogenic, neurogenic and myogenic lineages. Autologous ASCs are
multipotent and can be harvested with low morbidity; thus, they hold promise for a
range of therapeutic applications. This review will summarize the use of ASCs in muscle
regenerative approaches.
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Introduction
One major challenge of modern medicine is to repair damaged tissues. Self-adult stem cells
for regenerative therapies could overcome transplantation limitations such as organ rejection
or shortage of organs available for donation. Furthermore, many degenerative diseases such as
muscular dystrophies have no cure and the possibility to replace damaged muscle of the whole
body by transplantation, nowadays, is not feasible. In dystrophic patients, continuous myogenic
regeneration is sustained by resident stem cells. However, stem cell pool is eventually depleted,
which correlates with aggravation of the disease and deterioration of patients. Consequently,
cellular regenerative therapies that may replenish myogenic stem cell populations and counteract
muscle loss by producing healthy muscle could represent a new treatment to improve quality of life
and prevent early death for dystrophic patients. The potential use of adult adipose-derived stem
cells (ASCs) for muscle regeneration will be discussed.
Myogenic Progenitors from Different Sources
Intensive research has been done to identify different types of myogenic progenitors in
muscles that could be isolated, manipulated and expanded in vitro for therapeutic use
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reviewed in (Motohashi and Asakura, 2014). The classical stem
cell from muscle is the satellite cell (Mauro, 1961; Montarras
et al., 2005; Scharner and Zammit, 2011), however, in recent
years several groups have described other myoprogenitors in
muscle tissue such as muscle side-population cells (Gussoni
et al., 1999; Asakura and Rudnicki, 2002), muscle-derived stem
cells (Qu-Petersen et al., 2002), interstitial cells (Mitchell et al.,
2010), andmuscle-derived CD133 + stem cells (Benchaouir et al.,
2007). Other cells present in muscles called fibroadipogenic
progenitors have been shown to crosstalk with satellite cells
to enhance myogenesis (Joe et al., 2010; Uezumi et al., 2010).
Although muscle tissue seems to contain a high concentration
of progenitors (it is estimated that 550 satellite cells are
present in 1 mg of muscle tissue, Bentzinger et al., 2012),
muscle biopsies are difficult to obtain and are small, therefore
the yield of progenitors that can be obtained seems to be
insufficient for regenerative therapies. One approach to solve
this hurdle would be to expand progenitor population’s ex-
vivo, but unfortunately it has been shown to result in low
engraftment rates and failure to improve muscle strength in
Duchenne muscular dystrophy (DMD) patients (Mendell et al.,
1995; Vilquin, 2005). Interestingly, growing those progenitors
in different extracellular matrices and hydrogel platforms that
better mimic in vivo niche, could overcome this problem
(Gilbert et al., 2010). Nevertheless, satellite cells from Duchenne
dystrophic patients proliferate less, undergo rapid senescence
(Cossu and Mavilio, 2000) and are difficult to obtain due
to fiber fragility (Boldrin and Morgan, 2012). In addition,
muscle biopsies are still painful and can cause irreversible
damage to donors.
Therefore, additional sources of myogenic stem cells have
been explored such as embryonic stem cells (ESCs) and
induced pluripotent stem cells (iPS). Ectopic expression of
two regulators of myogenic transcription, BAF60c and MyoD,
were able to differentiate hESC towards myogenic lineage,
resulting in three-dimensional contractile structures called
myospheres (Albini et al., 2013). Whether those myospheres
could engraft in damaged muscle and contribute to regeneration
was not tested, nevertheless they could be a tool for drug
discovery to identify molecules that potentiate myogenesis.
In addition, myospheres generated from dystrophic patients’
iPS cells could open the way for tailored treatments in the
future. Overexpression of paired-box transcription factors
such as PAX3 (master regulator of embryonic myogenic
program) in mouse ESCs, and PAX7 (involved in maintenance
of satellite cell compartment) in human ESC and iPS cells,
converted these cells to myogenic lineage. Those cells were
then transplanted into immunodefficient Duchenne muscular
dystrophic mice, engrafted successfully to supply dystrophin
and repaired muscle strength. Importantly, in case of PAX7-
ESCs/-iPS the stem cell pool was restored (Darabi et al.,
2008, 2011, 2012). However, safety use of these genetically
modified embryonic or pluripotent cells needs to be carefully
addressed before they can be used in clinical setting. Some
concerns using these former approaches are related to
lentiviral usage for genetic modification of cells and the
need to fully reprogram them in order to avoid teratoma
formation and tumor progression when transplanted to
patients.
A safer and ethical-acceptable alternative could be the use
of adult multipotent stem cells such as mesenchymal stem cells
(MSCs), which are self-renewable and still able to differentiate
to several lineages in vitro. MSCs were first identified in bone
marrow (BM) by Friedenstein and colleagues (Friedenstein
et al., 1966, 1968), and subsequently MSCs have also been
found in many other adult tissues such as adipose, synovial
membrane, dermis, periosteum, dental pulp, peripheral and
menstrual blood, liver, spleen and lung (da Silva Meirelles
et al., 2006; Kassis et al., 2006; Zou et al., 2010). One
of most extensively studied MSC is the BM-derived, which
has been shown to differentiate towards myogenic lineage
in vitro (Pittenger et al., 1999). BM transplants contributed
to muscle regeneration in cardiotoxin-injured muscles and in
mdx mice (a model for DMD; Ferrari et al., 1998; Bittner
et al., 1999; Gussoni et al., 1999; Fukada et al., 2002;
Bossolasco et al., 2004). However, engraftment efficiency was
low and further research estimated that muscle repair by
BM-derived cells did not exceed 1% of total muscle fibers
during the lifespan of transplanted mdx mice. In addition,
this procedure did not contribute to ameliorate muscular
dystrophy symptoms (Ferrari et al., 2001). Most of these
works used whole BM populations and not purified MSCs;
thus, it is possible that limited myogenic potential was due
to little MSCs presence in total BM cells, being less than
0.01% in harvests that approximately yield 6 × 106 cells per
mL (Pittenger et al., 1999). In order to increase myogenic
engraftment of transplanted cells, BM-derived MSCs were
expanded and genetically modified ex-vivo to express PAX3.
When transplanted in dystrophic mice, PAX3 BM-derived MSCs
were able to activate myogenic program and to fuse successfully
with injured muscles, showing higher engraftments (10.8 +
3.6%) than previous works. Surprisingly and unfortunately, the
expected functional recovery was not observed (Gang et al.,
2009).
Another MSC type is adipose-derived mesenchymal stem cell,
which is now termed ASC. ASCs were characterized by Patricia
Zuk and colleagues, who isolated ASCs from lipoaspirates,
expanded them in vitro and showed their multipotentiality
towards not only adipogenic but also osteogenic, chondrogenic,
neurogenic and myogenic lineages upon culture with defined
media (Zuk et al., 2001). Could ASC represent a new and
powerful source of myogenic progenitors for regenerative
therapies?
Adipose Stem Cell Characterization
Compared to harvesting BM-derived MSCs, which requires
drilling into the bone, ASCs can be obtained by liposuction,
which is a less invasive procedure and may be more attractive
for donors due to its positive esthetic results. In addition,
stem cell yields are higher from adipose tissue, with 1 g
containing an average of 2 × 106 cells with 10% being
ASCs (Aust et al., 2004; Oedayrajsingh-Varma et al., 2006).
For this reason, adipose tissue represents an abundant and
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FIGURE 1 | Isolation, expansion and differentiation of ASCs. Adipose
tissue is obtained from lipoaspirates but it can also be obtained from other
surgeries. Upon digestion with collagenase type IA followed by
centrifugation; the pellet obtained is known as SVF. SVF is a mixture of
several types of progenitors and more differentiated cells. A majority of
cells (90–100%) are positive for mesenchymal stem cell surface markers,
and this fraction is the ASCs. Other markers such as CD146 and CD34 are
more controversial, and may represent subsets of other progenitors, which
vary in their ratios depending on anatomical origin of fat and other
parameters related to donors. In vitro culture of this proliferating
population, which can arrive to 70 PDs, can also alter percentages of
specific progenitors. Therefore, differential expression of CD markers and
their fluctuations may represent a heterogenic composition of ASCs, which
contain subsets of multipotent cells that can respond to differentiation cues
of other lineages (represented in red and yellow). Adipocyte is the main
lineage obtained from ASCs, however, upon culture with defined media, or
by ectopically expressing specific factors, myogenic, osteogenic and other
lineages can also be obtained. It is also possible that progenitors can
transdifferentiate (indicated by orange arrows) in response to lineage
specific cues.
practical source of multipotent stem cells for autologous and
heterologous cell transplantation approaches compared to other
tissues.
The protocol for ASCs isolation comprises an enzymatic
digestion of adipose tissue or lipoaspirate, with collagenase
type IA, followed by centrifugation (Figure 1). The pellet
is called stromal vascular fraction (SVF), which contains a
heterogeneous population of cells: fibroblast, red blood cells,
smooth muscle cells, pericytes, and preadipocytes. Freshly
isolated SVF can be plated with growth media (typically DMEM
+ 10% FBS) where a population of adherent cells proliferates
and can be expanded for several passage doublings (PDs)
in most cases without karyotype abnormalities (more than
70 PDs reported by; Rodriguez et al., 2005). This adherent
population is considered to be ASCs, which is characterized to
be positive for a specific set of surface mesenchymal markers:
CD13, CD29, CD44, CD49d, CD90, CD105 and negative for
hematopoietic markers such as CD11, CD14, CD31, CD45
and CD144 (Zuk et al., 2002; Katz et al., 2005; Mitchell
et al., 2006; Yoshimura et al., 2006; Varma et al., 2007;
Zannettino et al., 2008). Other CD markers have been more
controversial and with expressions showing variable percentages
amongst total ASCs population. For instance, many works
report that CD146 is not expressed by ASCs, however there
is data suggesting that a subset of ASCs express CD146 and
localize to areas surrounding blood vessels (Crisan et al., 2008;
Zannettino et al., 2008; Cai et al., 2011), arguing in favor that
a pericyte multipotent population resides in adipose tissue. A
CD34 + CD146- population with multipotent abilities has been
detected as well in the outer adventitial ring of vasculature
(Traktuev et al., 2008; Zimmerlin et al., 2010). Therefore,
all these works suggest that several lineage precursors may
be forming part of ASCs population (Zeve et al., 2009) and
that their relative composition present in isolated SVF may
reflect different anatomic origins of adipose tissues, as well as
other characteristics associated to donors such as age, body
mass index, gender and health conditions. In other words, the
particular niche of adipose tissue has an important role to
determine type and quantities of progenitors, and amore detailed
analysis needs to be performed in order to fully understand
Frontiers in Aging Neuroscience | www.frontiersin.org 3 July 2015 | Volume 7 | Article 123
Forcales Adipose stem cells for muscle regeneration
which subtypes of progenitors are better suited for a specific
regenerative aim.
Furthermore, it is important to note that upon culture
for several weeks some CD markers have been reported to
increase (CD105, CD166) while others such as CD146 and
CD34 decrease dramatically (Mitchell et al., 2006; Varma
et al., 2007). This can be explained by enrichment of certain
cell types during culture where diverse parameters such as
composition of basal media, supplements, plating substrates
or cell confluence could have an impact on this issue. The
media used for amplifying proliferating ASCs is a regular 10%
FBS in DMEM, and using other media with specific growth
factors and cytokines has not been tested systematically to
understand how it could impact on maintaining or selecting a
certain progenitor population. Conveniently, longterm cultured
ASCs express very little amounts of major histocompatibility
complex class I proteins and do not express class II proteins
(HLA-DP, DM and DR), which are crucial for antigen
presentation. As a result, absence of these molecules could give
an advantage for ASCs therapeutic usage, allowing evasion of
host’s immune response in heterologous transplantations (Lin
et al., 2012). Whether ASCs would upregulate human leukocyte
antigen (HLA) proteins upon myogenic differentiation is not
known.
In vitro Skeletal Muscle Differentiation
Potential of ASCs
The ability of ASCs to differentiate in vitro towards myogenic
lineage has been reported by several groups. Culture of ASCs
with myogenic differentiation media has resulted in ASCs
adopting an elongated morphology, similar to differentiating
myoblasts, and expression of early (MyoD1, myogenin) and
late (myosin heavy chain) markers of muscle differentiation
(Zuk et al., 2001; Mizuno et al., 2002; Zheng et al., 2006).
These and other works show variable differentiation efficiencies
in terms of onset and fusogenic ability, which may be the
result of using different inductive media (Table 1). Co-culture
experiments with myoblasts have shown that secreted factors
and cell-to-cell contacts induce ASCs myogenic conversion
and fusion with mouse C2C12 and primary myoblasts (Lee
and Kemp, 2006; Di Rocco et al., 2006; Eom et al., 2011).
Variations in fusogenic ability were observed when hASCs
were treated with myogenic differentiation media before co-
culture, and the highest efficiency was obtained when ASCs
were already at late stages of myogenic differentiation and
expressing myosin heavy chain (MyHC) and dystrophin (Eom
et al., 2011).
Importantly, for regenerative purposes as a treatment for
dystrophies, ASCs should also be able to fuse with dystrophic
myotubes, for this reason, Vieira and colleagues showed
that in vitro human ASCs could indeed fuse with DMD-
derived myoblasts to form myotubes that recovered dystrophin
expression (Vieira et al., 2008a). Therefore, these experiments
support the use of allogeneic ASCs not only for their
conversion towards the myogenic lineage and thus contributing
to counteract muscle loss, but also as providers ofWT dystrophin
and other potential beneficial factors that may be missing in
dystrophic muscles. The use of coatings and hydrogels has shown
to enhance myogenic differentiation from ASCs (Choi et al.,
2012). However, at present, a universal media composition for
a robust myogenic differentiation of ASCs is missing.
Table 1 summarizes the results showed in these works and
indicates the composition of differentiation media used in each
of them.
In vivo Skeletal Muscle Differentiation
Potential of ASCs
All these in vitro works indicate that different stimuli can
potentiate and promote ASCs differentiation towards myogenic
lineage, ranging from hormones and growth factors present in
media (or secreted by cells), to cell-to-cell contacts or even by
other mechanophysical inputs such as plating surfaces. However,
whether ASCs could contribute to myogenic regeneration in
vivo was not clear until the work of Rodriguez et al. (2005).
In this work, the authors characterized in vitro human ASCs
from different young donors and prior to transplantation
in mdx mice, they identified two multipotent populations,
one characterized to be fast adherent and expandable in
vitro for more than 200 passages (chosen for transplantation
experiments), and a slower adherent population that showed
senescent features upon long term culture. Interestingly, fast-
adherent ASCs at low-passages were HLA-I positive and HLA-
II negative whereas at later passages were HLA-I low and
HLA-II negative. Therefore, to assess whether absence of major
histocompatibility complex could be advantageous to evade host
immune’s system, the transplantations were performed in mdx
mice that were treated or not with 10 mg of cyclosporine A/kg
(daily i.p. injection) to immunosupress the host. Human ASCs
(1.5 × 105) from long-term passages (160 PDs) were injected in
left tibialis anterior (TA) muscle. Transplanted animals showed
expression of dystrophin at several days post-transplantation,
and human nuclei (elegantly revealed by FISH with a specific
probe for human centromeres) were observed in central and
peripheral locations of muscles, indicating that human-derived
ASCs contributed to the regenerative process. After 6 months,
dystrophin expression was well distributed along muscle fibers,
and even present in adjacent gastrocnemius muscle, suggesting
that cell migration from injection site to other dystrophic
muscles could have occurred or that dystrophin delivery was
achieved by another unknown mechanism. Furthermore, in
immunocompetent mice, regeneration took place successfully
with no evidence of CD3 positive-lymphocytic infiltration.
In contrast, hASC from early passages (that express HLA-
I antigens) elicited an immune response in the host and
could not restore dystrophin expression. Whether hASCs
contributed to regeneration not only by fusion but also by
converting themselves to myogenic lineage in vivo was not
clear, although in vitro conversion of ASCs to myogenic
lineage suggests that both mechanisms (fusion to myotubes
and also myogenic conversion of ASC themselves) could have
occurred. In this regard, the work of Liu et al. (2007), suggests
that not only fusion but also myogenic conversion of hASC
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TABLE 1 | Summary of ASC’s myogenic differentiation, engraftment and functional assessment.
Differentiation, engraftment, functional assessment Myogenic differentiation media
In vitro
Zuk et al. (2001) 12% myogenic differentiaton of hASCs from lipoaspirates. DMEM, 10% FBS, 5% horse serum, 0.1 µM dexamethasone
50 µM hydrocortisone, 1% Antibiotic-antimycotic
Mizuno et al. (2002) At 6 weeks of differentiation, aprox. 15% of hASCs expressed MyoD and
8.5% expressed Myosin heavy chain.
Same as Zuk et al. (2001) without dexamethasone.
Zheng et al. (2006) After 6 weeks of differentiation, mouse ASCs expressed desmin
monitored by immunofluorescence.
Same as Zuk et al. (2001).
Eom et al. (2011) C2C12-GFP/hASC cocultures; at day 21, myotubes showed 50% nuclei
from hASC origin.
LG-DMEM, 10% FBS, 3 µM 5-azacytidine (Sigma),
10 ng/ml FGF-2 (Sigma) for 24 h. Followed by 10% FBS,
10 ng/ml FGF-2 in LG-DMEM. Finally, hASC 5 days-filtered
supernatant (conditioned media) was used.
Di Rocco et al. (2006) Primary myoblasts and mASC-GFP direct cocultures showed 10-fold
higher myotube incorporation of ASCs than transwell cocultures. Green
myotubes expressed Troponin T by immunofluorescence.
DMEM high glucose, 5% horse serum, 2 mM L- glutamine,
1% penicillin-streptomycin.
Lee and Kemp (2006) Positive fusion of hASCs with C2C12 myoblasts as myotubes expressed
nestin from human origin monitored by immunofluorescence.
DMEM-high glucose (Gibco), 2% heat-inactivated horse
serum (Gibco), and 1% penicillin/streptomycin.
Vieira et al. (2008a) Coculture of DMD-derived myoblasts with GFP-hASCs. Fusion
successful monitored by dystrophin expression in green myotubes by
immunofluorescence.
hASCs passage 4 were cultured DMEM-HG, 10% FBS,
0.1 µM dexamethasone (Sigma), 50 µM cortisol (Sigma) and
5% HS (Gibco) for 45 days.
In vivo
Rodriguez et al. (2005) hASC injected in tibialis anterior muscles from mdx mice. Dystrophin was
detected in up to 50% of the myofibers analyzed per section 10 d after
transplantation. 10 to 50 d post- transplantation, 73 to 85% increase in
peripheral nuclei from hASCs; 27 to 15% decrease in central nuclei.
Skeletal Muscle Cell Differentiation medium (PromoCell).
Di Rocco et al. (2006) mASC from 6-week-old GFP+ mice were injected, after hind limb
ischemia, in the left adductor muscle of GFP negative mice. After one
week, GFP positive fibers represented up to 20% of the total area
of sections (38.33±8.82 GFP-positive fibers per mm2 of section area
calculated as an average from 8 experiments).
Dystrophin was detected in up to 10% of the myofibers analysed on
sections (11.7±2.94% dystrophin positive fibers per mm2 of section
area, average from 6 experiments).
DMEM high glucose, 5% horse serum, 2 mM L-glutamine,
1% penicillin-streptomycin).
Zheng et al. (2006) mASCs-LACZ injected in muscles of mdx mice. Few cells engrafted. Same as Zuk et al. (2001).
Liu et al. (2007) Cardiotoxin-injured mdx muscles injected locally with Flk1+ ASC:
dystrophin expression restored in many fibers. Central nuclei decreased
compared to controls at 4 weeks post-transplantation: 48.1% vs. 72.8%
(n=5), p = 0.05, and at 12 weeks post-transplantation: 43.3% vs. 74.2%,
n = 5, p = 0.05.
Decreased creatinine kinase concentrations in Flk1+ ASCs-treated mice
compared to controls at 12 weeks post transplantation: 5,321.6 +/−
1,289.75 vs. 13,746.8 +/− 5,373.75 Ul−1, n = 5, p = 0.005).DMEM
containing 2% fetal bovine serum (FBS), 5% horse serum (Gibco), 50µ M
hydrocortisone (Sigma), 100 U/ml penicillin, and 100 µg/ml streptomycin
(Gibco).
Vieira et al. (2008b) Systemic delivery of hASC in SJL mice (tail vein injection). Human
Dystrophin found in approx. 50% +/− 2% (p = 3.623 × 10−13, Student’s
t test, n = 7) of the fibers.The treated group showed an improvement of
15.2% +/− 7.0% in their performance, whereas the untreated worsened
6.12% +/− 6.0% (p = 0.013, Student’s t test, n = 7).
Same as in Vieira et al. (2008a), during 10 days before
transplantation to SJL mice. At this stage, hASCs cells
express MyoD.
Goudenege et al. (2009) Tibialis anterior muscles of Rag2−/−γC−/− mice injected with MyoD-
hASCs show between 27 and 38 spectrin-positive fibers per section
whereas ASCs injected muscles show less than 10 spectrin-positive
fibers per section.
1.5 g/l glucose Dulbecco’s modified Eagle’s medium
supplemented with 10 µg/ml insulin and 5 µg/ml transferrin
when the cells reached 90% confluence.
(Continued)
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TABLE 1 | Continued
Differentiation, engraftment, functional assessment Myogenic differentiation media
Vieira et al. (2012) Systemic injections of hASC in GRMD dogs showed variable dystrophin
expression by WB (11 to 19% where 100% corresponds to normal
human muscle). Immunofluorescence for dystrophin showed compatible
results. hASC local injection in muscles of GRMD dogs did not engraft
(hASCs not present in muscles 1 month after transplantation).
Same as Zuk et al. (2001).
Composition of myogenic differentiation media used in different works is also indicated.
occurs in vivo since expression of myogenic markers (MyoD,
Myogenin, MyHC) from human origin could be detected by
RT-PCR with specific primers. In this work, a subset of hASCs
expressing endothelial marker Flk1 were transplanted by two
different methods in two different regeneration models: tail
vein injection (systemic) in cardiotoxin-injured TA muscles or
intramuscular injection (local) in mdx mice. They both resulted
in successful engraftment, partial recovery of sarcolemmal
expression of dystrophin, decreased necrosis after 4 weeks
and lower levels of muscle creatinine kinase in blood after
12 post-transplantation weeks. Importantly, the satellite stem
cell pool seemed to be replenished from hASC since positive
PAX7 cells co-stained for the human protein β2M. Another
work (Vieira et al., 2008b), also transplanted hASCs by tail-
vein injection in a SJL mice, a model of limb girdle muscular
dystrophy 2B which is milder than Duchenne’s. Different
from in vitro co-culture experiments where highest fusion
was observed using hASCs differentiated to late myogenic
stages (Eom et al., 2011), undifferentiated hASC, but not
hASC previously differentiated to myogenesis in vitro, were
able to engraft successfully in muscles and provide expression
of dysferlin and dystrophin of human origin. This data
suggests that a progenitor state is more suitable to use
in transplantation approaches, perhaps this undifferentiated
population is more competent to receive regenerative signals
from in vivo niche than more differentiated cells do, and
this ‘‘instructive’’ step may be necessary in order to fuse to
injured muscle. Also, it is possible that myogenic-differentiated
ASCs are not able to sustain a proliferating pool of cells that
could give cycles of regeneration upon time, which may be
required to achieve robust and successful engraftments. These
authors also reported that inflammatory process shown by
those dystrophic muscles from SJL mice, did not improve
upon hASC transplantation, in contrast to other works, which
have reported a beneficial immunoprotective effect of ASC
transplantation, for instance in rat brains upon a hemorrhagic
stroke (Kim et al., 2007) and in an osteoarthritic mice model
(ter Huurne et al., 2012). Nevertheless, mice showed improved
muscle functionality in several motor ability tests up to 6 months
of transplantation.
To assess the viability of cell transplantation approaches in
humans, it is crucial to validate whether they can be feasible
in larger animal models. This issue is important in order to
predict pathogenesis and treatment outcomes. An alternative
bigger model than mice and rats for muscle regeneration is
the golden retriever muscular dystrophy (GRMD) dog. This
model reproduces full spectrum of human DMD and it has
been used for successful transplantation studies with systemically
injected mesoangioblasts, which is a type of mesenchymal stem
cell present in walls of large vessels. In these experiments,
dystrophin expression was recovered as well as partial muscle
functionality (Sampaolesi et al., 2006). However, the dogs were
immunosuppressed and treated with steroids, which have been
shown a beneficial impact on muscle functionality. For this
reason, Vieira et al., 2012, assayed the transplantation of hASCs
in GRMD dogs that were not immunosuppressed. hASCs were
injected systemically into the dog cephalic vein (5 × 107 cells/kg
in 0.1 ml of Hank’s buffered salt solution) and engrafted
successfully in the muscles. Expression of human dystrophin
was validated up to 6 months after transplantation but could
not be found after 12 months, suggesting that hASCs were
not able to replenish the stem cell pool. The percentage of
human dystrophin expressed in muscles was small (ranging
from 6% to 19%) as monitored by immunofluorescence and
immunoblotting. Unfortunately, histopathological features were
not improved and beneficial effects on disease symptoms were
difficult to be concluded. Therefore, from these data one can
speculate that perhaps multiple injections, for instance every 6
months, and larger amounts of cells may be required to maintain
exogenous dystrophin expression at levels that give a positive
functional output. Surviving animals did not present adverse
immune responses or other complications after 24 months,
which might indicate ASC transplantation to be a safe procedure.
In contrast, locally injected hASC were not able to engraft
successfully, opposite to what had been described for mdx mice
(Rodriguez et al., 2005; Liu et al., 2007).
Table 1 summarizes the results showed in these works
and indicates quantifications of ASCs contribution to muscle
differentiation and regeneration.
MyoD-Driven Conversion of ASCs
From all these works it is suggested that ASCs can be
reprogrammed to myogenic lineage in vitro and in vivo by
extracellular cues, highlighting a possible therapeutic use of ASCs
as a new source of myogenic progenitors. However, efficiency
of this conversion is not 100%, suggesting that there is a
subpopulation of ASCs receptive to myogenic-commitment cues
and a non-responsive population. In order to increase levels
of myogenic conversion, Goudenege et al., 2009, genetically
manipulated ASCs to express MyoD1, a transcriptional factor
crucial for myogenic differentiation. MyoD1-pioneering ability
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was suggested years ago by Weintraub and colleagues, who
ectopically expressed MyoD1 in fibroblasts, fat, liver and nerve
cell lines resulting in activation of myogenic gene expression
(Weintraub et al., 1989, 1991). Fibroblasts harboring an inducible
MyoD1 system and µdystrophin gene were able to convert
to myogenic lineage and contribute to muscle regeneration in
mdx mice (Kimura et al., 2008). In ASCs, overexpression of
MyoD1 resulted in upregulation of CD56, a surface marker
of myogenic progenitors committed to differentiate (Capkovic
et al., 2008), from 2% to 30% of total ASCs (Goudenege
et al., 2009). Those MyoD1-expressing hASCs could efficiently
form multinucleated myotubes in vitro upon culture with
differentiation media (containing 10 µg/ml insulin and 5 µg/ml
transferrin when cells reached 90% confluence), as well as
to fuse with human DMD-derived myoblasts in vitro. Upon
transplantation in a mouse model for regeneration (cryoinjury
in TA muscles of Rag2−/−γC−/− immunodeficient mice), hASC
engraftment was monitored by immunofluorescence against
human Lamin A/C, revealing that hASC localized between fibers
and also integrated in regenerating muscles. To assess hASC
contribution to regenerative process, several human specific
muscle proteins (spectrin, dystrophin, and δ-sarcoglycan) were
detected by immunofluorescence at the membrane of different
fibers. Muscles transplanted with MyoD1-hASCs seemed to
contain higher number of positive human-derived myogenic
marker-expressing fibers than WT-hASCs, indicating that
MyoD1 expression in ASCs results in higher regenerative in vivo
potential. This data argues in favor of manipulating ASCs in vitro
with transcriptional factors to force ASCs commitment towards
myogenic lineage, since using these manipulated ASCs result in
a higher contribution to muscle regeneration. Whether those
MyoD1-ASCs contribute to functional recovery of damaged
muscles remains to be tested and perhaps MyoD1-hASC should
also be assayed in DMD models such as mdx mice and GRMD
dogs.
Epigenetics of ASC-Derived Myocytes
During adult stem cell differentiation as well as in the progression
from a pluripotent to a multipotent state, expression of
proliferative and pluripotent genes is erased, and expression of
differentiation or lineage-specific genes from previously silent
loci is activated. This process is controlled by concerted action
of signaling cues with ubiquitous and cell-specific transcription
factors that govern a changing epigenetic landscape during
cellular differentiation. In other words, distinct epigenetic
signatures can be associated to a precise cellular stage (Hussein
et al., 2014; Tee and Reinberg, 2014).
DNA methylation at CpG sites is one of best-studied
epigenetic modifications, which has been associated to gene
repression (Heard et al., 1997; Walsh et al., 1998; Gaudet
et al., 2003), although it is also found in gene bodies of
highly transcribed genes (Jjingo et al., 2012). DNA methylation
fluctuates during early mammalian development (Reik, 2007),
but it is quite stable in most of the cells, which show an
average of 70–80% of methylated CpGs. Nevertheless, global
analyses in different cell types and tissues have shown that a
dynamic regulation occurs for almost 22% of autosomal CpGs
at enhancers of lineage specific regulators (Hon et al., 2013; Ziller
et al., 2013; Carrió et al., 2015), suggesting that DNAmethylation
at CpG sites is an epigenetic feature that determines cellular
identity.
Therefore, to verify a certain lineage reprograming,
conversion, or proper differentiation, instead of monitoring
expression of a few markers of these processes, global
characterization of gene expression and epigenetic patterns
seems to be a more complete approach to validate whether
a full or partial conversion has been achieved. Berdasco and
colleagues pursued this technique and characterized global
DNA methylation status of myogenic lineages derived from
hASC by Infinium methylation arrays interrogating 27,578
CpG sites (Berdasco et al., 2012). Their results indicate that
methylome of ASCs-derived myocytes is more similar to the
one of undifferentiated ASCs than to the one of primary
myocytes from human biopsies. ASCs methylome shared the
lowest similarity with a rhabdomyosarcoma cell line, a pediatric
muscle tumor. Importantly, methylomes of ASCs and ASCs-
myogenic derivatives did not show hypermethylation of tumor
suppressor genes, a hallmark of DNA methylation profiles of
cancer cells. Hence, these results argue in favor of ASCs as
a safe cell population for therapeutic purposes. Intriguingly,
these data show that although ASC-derived myocytes and
primary myocytes present overlapping methylomes, ASC-
derived myocyte methylome is more similar to the one of
undifferentiated ASCs. Therefore, this result could imply
several interpretations such as incomplete conversion towards
myogenic lineage of all ASCs, or that just a subset of isolated
ASCs was converted to myogenic lineage while the rest were
resistant to this conversion. It could also imply that many of
the observed 2,313 differential methylated regions between
ASC-derived myocytes and primary myocytes, are not essential
for myogenic differentiation, which indeed took place in
ASC-derived myocytes supported by positive expression of α-
sarcomeric actin, actinin and troponin by immunofluorescence.
In any case, other epigenetic mechanisms different from DNA
methylation may be crucial for lineage plasticity contributing
to reprogram ASCs towards myogenic lineage. In fact, a direct
link between DNAmethylation state and differentiation capacity
is not obvious as for instance mesenchymal stem cells from
adipose, BM and skeletal muscle all show lineage-specific genes
hypomethylated (Sørensen et al., 2010).
A comparative epigenomic profiling in murine and human
models of adipogenesis, which monitored genome-wide
distribution of several histone modifications, CTCF and adipose
specific transcriptional factor peroxisome proliferator-activated
receptors (PPARγ), was able to identify two novel players,
promyelocytic leukaemia zinc finger (PLZF) and serum response
factor (SRF), with anti-adipogenic activity (Mikkelsen et al.,
2010). A positive correlation was found between gene expression
values and presence of H3K27ac in enhancer regions, giving to
this modification a predictive value when present. This work
also suggested that gain of histone acetylation accompanying
PPARγ binding, distinguishes functional PPARγ binding sites
from nonproductive ones. Surprisingly, a major number of
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PPARγ binding sites were different in mouse and human, and
many were associated to rodent-specific transposable elements.
This work shows that adipogenesis may not be 100% equivalent
in mice and humans, implying that regulation of ASC plasticity
may be different as well. Whether PLZF and SRF could play a
role in early stages of myogenic determination of ASCs remains
to be elucidated.
Considerations for Use of ASCs in Muscle
Regenerative Therapies
Previously mentioned studies support the idea that ASCs are a
promise for muscle regenerative therapies: they can differentiate
towards myogenic lineage, they can be obtained in great
quantities by simple liposuction, and they may represent a
safer alternative to embryonic or induced pluripotent stem
cells, which can produce tumors if full reprograming is not
achieved. Autologous transplantations of ASCs have been safely
used for reconstructive surgery and wound healing therapies for
several years (Ross et al., 2014), nevertheless, clinical studies
are scarce to confirm long-term safeness of ASC transplants
(Barkholt et al., 2013). Whether allogeneic ASC transplants
in humans would work for muscular dystrophy treatment is
not known, but successful engraftments of ASCs in muscles of
immunocompetent mice support the idea that they might.
However, for successful muscular regenerative therapies it is
necessary that transplanted ASCs not only engraft in muscles but
also that differentiate efficiently resulting in a positive functional
output. At present, ASCs’ efficiency to differentiate towards
myogenic lineage is low and their contribution to recover muscle
function in in vivo regenerative models is not consistent. Stem
cell research from skeletal muscle and hematopoietic fields
have reported that stem cells are heterogeneous regarding self-
renewal, proliferation and lineage output (Copley et al., 2012;
Malecova and Puri, 2012), supporting a view of mixture of
progenitors in those tissues. Adipose tissue is emerging as a
new crucial player in the endocrine field, and the former idea
that it is just a reservoir of energy, in form of lipid deposits,
is changing. Therefore, it is not surprising to find different
types of progenitors also present in this complex tissue. ASCs
comprise a mix of multipotent progenitors, which seem to vary
in their composition depending on several factors such as donor
characteristics or their anatomical origin. Perhaps, anatomical
location defines subsets of stem cells, which may respond better
to signals of that particular environment. Supporting this idea,
ASCs derived from epicardial adipose tissue differentiate poorly
towards adipocyte lineage, whereas they express myocardial and
endothelial markers in vitro. Furthermore, when transplanted
into injured hearts they are able to differentiate into cardiac cells,
engraft successfully and promote paracrine effects to induce local
vascularization in mouse, rat and porcine models of myocardial
infarction (Bayes-Genis et al., 2010, 2013). Consequently, not all
adipose tissue from the body has the same characteristics and
more research is needed to identify molecular determinants that
define their specificities. It is quite plausible that extracellular
niche plays an important role in this issue; however signaling
pathways that control stem cell pools in adipose tissue as well
as their crosstalks with adjacent normal or diseased organs are
still poorly understood. In regenerating dystrophic muscles of
mdx mice, recently identified fibroadipogenic progenitors play
a crucial role by enhancing muscle progenitor differentiation
as well as modulating the inflammatory response that leads to
fibrosis (Mozzetta et al., 2013). Also, parabiotic experiments
suggest that age-related changes in systemic environment and
the niche in which progenitor cells reside prevent complete
activation of these cells for successful muscle regeneration
(Conboy et al., 2005). Thus, these and other works show that
tissue homeostasis involves interplay of local and systemic
factors, and it is far more complex than previously anticipated.
In vivo skeletal muscle regenerative experiments using ASCs
suggest that there is a subset of cells with increased myogenic
capacity, which argues in favor of a myoprogenitor population
present in ASCs. Therefore, identifying this myoprogenitor
ASCs with specific surface markers could allow their isolation
and expansion for a successful therapeutic use. Encouragingly,
for bone regenerative purposes, Chung and colleagues have
identified a population of CD90-high expressing ASCs, which
show increased osteogenic capacity in mice models of bone
regeneration (Chung et al., 2013). However, regarding ASC-
derived myoprogenitors it is not clear which marker may identify
them. Myoprogenitor marker CD56 is only present in 2% of
cultured ASCs (Goudenege et al., 2009), which seems a small
percentage of cells to account for the observed ASCs myogenic
capacity. Intriguingly, in ASCs there is a 29% of CD146 + cells
(Zannettino et al., 2008), but whether those cells contain type II
pericytes with ability to regenerate muscles after injury (Birbrair
et al., 2013) is not clear. Flk1 + cells purified from ASCs showed
high myogenic differentiation potential, and although Flk1 is
considered to be an endothelial marker (Yamaguchi et al., 1993),
cardiac stem cells seem to express Flk1 (Iida et al., 2005). Perhaps,
single cell analyses similar to those performed for muscle stem
cells (Sacco et al., 2008) could help to identify and characterize
a group of myoprogenitor markers in ASCs that could be
instrumental to isolate a progenitor fraction with enhanced
myogenic properties more suitable for muscle regenerative goals.
Other works suggest that transdifferentiation of ASCs towards
myogenic lineage is also possible, although whether this
transdifferentiation includes reprograming to a myoprogenitor
or direct differentiation is not clear. While transcriptional
programs that direct adipocyte and myocyte differentiation
are well studied and many players have been identified such
as insulin-like growth factor 1 (IGF-1), bone morphogenetic
protein (BMP), transforming growth factor beta (TGFB),
retinoic acid, integrins, Ncadherin, galectin, cAMP response
element-binding protein (CREB), PPARg, p38 kinase, MyoD,
BAF60c, myocyte enhancer factor-2 (Mef2), ASH2 (Rosen and
MacDougald, 2006; Perdiguero et al., 2009; Cristancho and
Lazar, 2011; Dilworth and Blais, 2011; Giordani and Puri,
2013), early molecular events that determine which fate ASCs
will follow are mostly unknown. Shed new light on this issue
and showed that inhibition of Rho-ROK signaling pathway
in differentiating myocyte precursors (C2C12 in presence of
IGF1), blockedmyogenic differentiation in favor of adipogenesis,
while excessive Rho activation in adipocyte precursors (L1–3T3)
Frontiers in Aging Neuroscience | www.frontiersin.org 8 July 2015 | Volume 7 | Article 123
Forcales Adipose stem cells for muscle regeneration
blocked adipogenesis Sordella et al. (2003). The phosphorylation
status of p190-B RhoGAP would be a sensor of this pathway.
Other works have shown that in a mesenchymal stem cell
population, a dominant negative RhoA expression induces
adipogenesis whereas a constitutively active RhoA drives
osteogenic differentiation (McBeath et al., 2004). These works
highlight important roles of Rho pathway modulating cell fate
decisions in MSC. Whether this pathway controls adipose vs.
myogenic fate of ASC in response to IGF1 remains to be
elucidated.
One of the signaling pathways involved in cell fate during
development and also in cancer disease is Sonic Hedgehog.
Eric Olson’s group has described that constitutive activation of
Sonic Hedgehog signaling in adipose lineage results in skeletal
muscle tumors that resemble embryonal rhabdomyosarcomas
(Hatley et al., 2012). This work supports a transdifferentiation
hypothesis of an adipose progenitor towards muscle lineage, and
importantly it reminds us the need tomake sure ASC progenitors
used for therapy are not harboring mutations or activated signals
that can lead to cancer. In vitro and in vivo assays show that
ASCs are not intrinsically tumorigenic cells, however they could
enhance tumorigenic behavior of c-Met+ breast cancer cells
by eliciting an inflammatory microenvironment that sustained
tumor growth (Eterno et al., 2014). In other words, using ASC
in esthetic procedures for breast reconstruction after cancer
could enhance recurrence at least in c-Met+ tumors. Thus,
more research is needed to better understand ASC biology upon
transplantation and ensure safeness for clinical applications.
Epigenetic modifications are catalyzed by enzymes that can
be targeted by drugs; hence, these drugs have an impact on
cell fate. For instance, use of demethylating drug 5-Azacytidine
in fibroblasts resulted in their conversion to chondrocytes,
adipocytes and contractile muscle striated cells (Taylor and
Jones, 1979) illustrating the broad effect this drug had on
demethylation of many lineage regulatory loci. Therefore, in
order to control a specific lineage conversion at will, it is
necessary to find more precise strategies. In this regard, CRISPR-
CAS technology holds great potential for targeted approaches
to gene therapy. Perhaps it could be used for several objectives
ranging from recruiting desired epigenetic enzymes to specific
lineage regulatory loci to activate known myogenic regulators in
ASCs, or to target dystrophin gene in order to fix its mutations
in autologous DMD-cultured ASCs. Alternatively, this strategy
could also be used to activate expression of myogenic booster
genes (Engvall andWewer, 2003) in ASCs, which could then fuse
to muscles to alleviate muscular dystrophy symptoms.
In conclusion, several works have shown promising data
on ASCs contribution to muscle regeneration. ASCs safety
is supported by in vivo transplantation experiments and
epigenetic data. Identification of new protocols and tools that
allow enrichment, expansion and manipulation of ASC-derived
myoprogenitors could help to boost muscle regeneration.
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